Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Amplo Biotechnology is to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction.
NysnoBio helps patients with medical conditions develop the Parkin protein's therapeutic potential.
Cure Rare Disease is a biotechnology company.
Rocket Pharmaceuticals is a biotech company that develops a pipeline of genetic therapies for rare childhood disorders.
Calidi Biotherapeutics is a clinical-stage biotechnology company developing immunotherapies for cancer.
Entos Pharmaceuticals is a clinical-stage biotech company developing genetic medicines with its Fusogenix PLV drug delivery platform.
Kenai Therapeutics focuses on developing therapies for neurodegenerative movement disorders.
Tr1x is a biotechnology company developing novel cellular immunotherapies for patients with autoimmune and inflammatory diseases.
Angiocrine Bioscience develops a cellular platform to amplify stem and progenitor cells in both human and mouse models.
Mustang Bio is a clinical-stage biopharmaceutical company .
Nexcella Utilize cell therapies to create safe and effective medicines for oncology and other conditions, improving patient outcomes.
Rejuvenate Bio is a biotechnology company that develops therapies to reverse aging and treat age-related diseases.
Luxa Biotechnology is a clinical-stage biotechnology firm developing a unique adult RPE stem cell (RPESC) therapy for dry AMD.
Denovo Biopharma is a privately held biotech company providing a novel biomarker solution to personalize drug development.
Anova Enterprises accelerates clinical development of promising therapeutics through improved access, collaboration and data.
Greenstone Biosciences is a drug discovery platform that accelerates the development of effective therapies for patients.
Combangio is a clinical-stage biotechnology company focused on developing regenerative biotherapeutics.
Tachyon Therapeutics develops novel, selective compounds to improve the treatment of cancer.
Clinical-stage biotechnology company developing life-changing gene therapy products for musculoskeletal diseases
AIVITA Biomedical is is a medicine company develops commercial and clinical stage programs utilizing curative and regenerative medicines.
Medeor Therapeutics is a biotechnology company that dedicates to dedicates to the development of personalized cellular immunotherapies.
California Institute for Regenerative Medicine has invested in 49 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
California Institute for Regenerative Medicine's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 16 different industry categories.
Among tracked funding rounds, Rocket Pharmaceuticals received $165.0M in a Post-IPO Equity round. California Institute for Regenerative Medicine's total known invested capital is $771.3M.
California Institute for Regenerative Medicine's average investment size is $22.0M across its portfolio of 49 companies.
Recent California Institute for Regenerative Medicine portfolio additions include Amplo Biotechnology, NysnoBio, Cure Rare Disease, Rocket Pharmaceuticals, Calidi Biotherapeutics. These companies were founded in 2020 or later.